Last reviewed · How we verify
BMS-986168
At a glance
| Generic name | BMS-986168 |
|---|---|
| Also known as | Other Names: BIIB092 |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (PHASE2)
- Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PHASE2)
- Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 (PHASE1)
- Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy (PHASE1)
- A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |